Sign in
TerminatedPhase 1/2

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

Key facts

Who runs it
Loyola University
Where
Maywood, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
3 people enrolled
Started
20 Dec 2017
Ended
26 Jul 2024
Type of study
Interventional
Treatments tested
  • HDR Brachytherapy + EBRT + STAD
Record updated
29 January 2026
Why it stopped
The study was stopped for feasibility

Who can take part

Age
18 years to 99 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Biopsy proven locally recurrent adenocarcinoma of the prostate after the completion of definitive radiation therapy for initially diagnosed prostate cancer
  • Initial cancer diagnosis that fits these specific criteria:; Stages cT1-T3a; Nx or N0; Mx or M0
  • Eligible initial definitive radiotherapy modalities include:; External beam radiotherapy, with photon or proton beam therapy; Definitive Brachytherapy; Stereotactic Body Radiotherapy
  • Fluciclovine-positive pelvic nodes (as determined by an interpreting radiologist or nuclear medicine physician) in the pelvic nodal region (defined as the pelvic nodal regions up to the common iliac nodal region) without any evidence of lymph node involvement outside of this area or distant metastases
  • Candidate for hormonal therapy
  • Current ECOG Performance status Scale 0-2 (Appendix D)
  • Current International Prostate Symptom Score (IPSS) < 20 (Appendix B)
  • Age >18
  • The patient must be medically suitable to receive general or spinal anesthesia
  • AST, ALT, and alkaline phosphatase < 2 x upper institutional limit within 3 months of registration
  • The patient must be able and willing to sign a study-specific written informed consent form before study entry

Who cannot take part

  • Preregistration radiation-related GI or GU toxicity (for any reason) grade ≥ 3 as defined in CTCAE version 4.03. That is, grade ≥ 3 GU or GI toxicity after first course of radiotherapy
  • Treatment to a "whole pelvis" field with initial radiotherapy
  • Patients receiving any other investigational agents
  • Patients who have received chemotherapy or immunotherapy within one month prior to study enrollment, other than ADT
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, severely symptomatic congestive heart failure, cardiac arrhythmia, recent myocardial infarction in last 6 months, or psychiatric illness/social situations that could limit compliance with study requirements
  • Patients with distant metastases (such as to the bone, visceral organs, and lymph nodes other than the pelvic nodes including the common iliac nodes)

Where in United States

  • Loyola University Medical CenterMaywood, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and effectiveness of combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) to the pelvis and 6 months of hormonal therapy, otherwise known as short term androgen deprivation therapy (STAD), as treatment for prostate cancer that has come back in the prostate and pelvic lymph nodes after prior radiotherapy. The study will examine the side effects of the treatment as well as the ability of the treatment to get rid of the cancer. This involves the placement of a radioactive material in the affected area of the prostate temporarily, and then is subsequently removed using a minimally invasive technique. Participants will also receive external radiation for 5 weeks targeting the pelvis and giving a higher dose each day to the suspicious lymph nodes on PET scan. Radiation therapy will start approximately 2 months after the start of the Androgen Deprivation Therapy (hormone therapy). The hormone therapy consists of two medications, an oral medication taken daily 2 months before starting radiation therapy until the last of the radiation therapy and an injection of a medication which is given 2 months prior to the start of radiation. Patient are then followed at specific time intervals to evaluate the treatment side effects and cancer control

The group in the trial

  • HDR Brachytherapy + EBRT + STADTreatment being tested

    Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV. EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions. 6 months hormonal therapy(LHRH agonist and antiandrogen \[until the end of radiotherapy\])

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/II Study of Salvage High-dose-rate Brachytherapy, ExternAl Beam COmbined and Short-term Hormonal Therapy for the Treatment of Node-positive Locally Recurrent Prostate Cancer After Prior Definitive Radiotherapy
Record updated
29 January 2026